Investors & Media Investor Relations Overview Press Releases Scientific Publications & Presentations Corporate Deck Events & Presentations Press Kit Corporate Governance Financial Info Stock Info Analyst Coverage Investor Resources Stock Information Data Provided by Refinitiv. Minimum 15 minutes delayed. Press Releases Jun 24, 2022 Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose Read More Events & Presentations More events are coming soon. Contact IR
Stock Information Data Provided by Refinitiv. Minimum 15 minutes delayed. Press Releases Jun 24, 2022 Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose Read More Events & Presentations More events are coming soon.
Jun 24, 2022 Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose Read More